Congenital Hyperinsulinism Treatment Market by Indication Type (Atypical Congenital Hyperinsulinism, Diffuse Congenital Hyperinsulinism, Focal Congenital Hyperinsulinism), Treatment (Dietary Management, Drugs, Surgical Intervention), Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030
The Congenital Hyperinsulinism Treatment Market size was estimated at USD 182.53 million in 2023 and expected to reach USD 192.20 million in 2024, at a CAGR 5.61% to reach USD 267.64 million by 2030.
Congenital hyperinsulinism (CHI) is a complex condition characterized by excessive insulin production in infants and children, leading to severe hypoglycemia. CHI treatment options are multifaceted, aiming to maintain blood glucose levels within a normal range and prevent hypoglycemic episodes. These include medical therapies such as diazoxide, octreotide, and newer drugs like lanreotide, as well as surgical interventions in more severe cases. The major factors contributing to the expansion of CHI treatment options include advancements in diagnostic methodologies, improved understanding of the genetic and molecular bases of the disease, and the development of novel pharmacological agents targeting specific pathways involved in insulin secretion. However, treatments for CHI come with challenges, including potential side effects, such as fluid retention with diazoxide or gastrointestinal symptoms with octreotide, and the risk of incomplete relief from symptoms or hypoglycemia recurrence. Addressing these challenges involves ongoing research into more targeted and less invasive therapeutic strategies, personalized medicine based on genetic profiling, and developing more effective and safer drugs. The advent of artificial pancreas systems that could regulate insulin production and release in real-time offers a transformative approach to managing CHI, providing advanced treatment for the condition.
Please Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increase in prevalence of congenital hyperinsulinism disease
- 5.1.1.2. Government initiatives promoting congenital hyperinsulinism diagnosis
- 5.1.2. Restraints
- 5.1.2.1. Limited reimbursement available for congenital hyperinsulinism
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing R&D for advancing treatment of congenital hyperinsulinism
- 5.1.3.2. Emerging approval of congenital hyperinsulinism treatments
- 5.1.4. Challenges
- 5.1.4.1. Diagnostic challenges and possible complications of the treatment
- 5.2. Market Segmentation Analysis
- 5.2.1. Indication Type: Need for a more personalized approach to treat Atypical CHI
- 5.2.2. End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals
- 5.3. Market Disruption Analysis
- 5.4. Porter’s Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
- 5.5. Value Chain & Critical Path Analysis
- 5.6. Pricing Analysis
- 5.7. Technology Analysis
- 5.8. Patent Analysis
- 5.9. Trade Analysis
- 5.10. Regulatory Framework Analysis
- 6. Congenital Hyperinsulinism Treatment Market, by Indication Type
- 6.1. Introduction
- 6.2. Atypical Congenital Hyperinsulinism
- 6.3. Diffuse Congenital Hyperinsulinism
- 6.4. Focal Congenital Hyperinsulinism
- 7. Congenital Hyperinsulinism Treatment Market, by Treatment
- 7.1. Introduction
- 7.2. Dietary Management
- 7.3. Drugs
- 7.4. Surgical Intervention
- 8. Congenital Hyperinsulinism Treatment Market, by Route of Administration
- 8.1. Introduction
- 8.2. Oral
- 8.3. Parenteral
- 9. Congenital Hyperinsulinism Treatment Market, by Distribution Channel
- 9.1. Introduction
- 9.2. Hospital Pharmacies
- 9.3. Online Pharmacies
- 9.4. Retail Pharmacies
- 10. Congenital Hyperinsulinism Treatment Market, by End-Users
- 10.1. Introduction
- 10.2. Ambulatory Surgery Centers
- 10.3. Hospitals
- 10.4. Specialty Clinics
- 11. Americas Congenital Hyperinsulinism Treatment Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Congenital Hyperinsulinism Treatment Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Congenital Hyperinsulinism Treatment Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2023
- 14.2. FPNV Positioning Matrix, 2023
- 14.3. Competitive Scenario Analysis
- 14.3.1. C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement
- 14.3.2. Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism
- 14.3.3. Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
- 14.4. Strategy Analysis & Recommendation
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.2. Key Product Portfolio
- FIGURE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. CONGENITAL HYPERINSULINISM TREATMENT MARKET DYNAMICS
- FIGURE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
- FIGURE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 20. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 26. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook